Picture of Agios Pharmaceuticals logo

AGIO Agios Pharmaceuticals Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Annual cashflow statement for Agios Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-411-3271,605-232-352
Depreciation
Non-Cash Items78.897.7-1,984-69.868.5
Discontinued Operations
Unusual Items
Other Non-Cash Items
Changes in Working Capital-46-71-36.8-16.4-19.1
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities-371-291-407-309-296
Capital Expenditures-12.2-14.9-5.74-4.88-0.999
Purchase of Fixed Assets
Other Investing Cash Flow Items10490.71,255248241
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities91.475.71,249243240
Financing Cash Flow Items025100
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities290262-7662.355.43
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash10.446.575.7-63.9-51.1